These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33787859)

  • 1. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma.
    Parmar H; Gertz M; Anderson EI; Kumar S; Kourelis TV
    Blood Adv; 2021 Apr; 5(7):1797-1804. PubMed ID: 33787859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.
    Kourelis TV; Villasboas JC; Jessen E; Dasari S; Dispenzieri A; Jevremovic D; Kumar S
    Blood Cancer J; 2019 Aug; 9(9):72. PubMed ID: 31462637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
    Coffey DG; Osman K; Aleman A; Bekri S; Kats S; Dhadwal A; Catamero D; Kim-Schulze S; Gnjatic S; Chari A; Parekh S; Jagannath S; Cho HJ
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
    Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
    Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
    Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
    Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
    Front Immunol; 2021; 12():618610. PubMed ID: 33717112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
    Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
    Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
    Minnie SA; Hill GR
    Front Immunol; 2021; 12():651288. PubMed ID: 33777050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
    Derman BA; Zha Y; Zimmerman TM; Malloy R; Jakubowiak A; Bishop MR; Kline J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma.
    Janakiram M; Arora N; Bachanova V; Miller JS
    Transplant Cell Ther; 2022 Feb; 28(2):61-69. PubMed ID: 34634499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
    Kansagra A; Gonsalves WI; Gertz MA; Buadi FK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Kapoor P; Muchtar E; Kourelis TV; Warsame R; Leung N; Zeldenrust SR; Lust JA; Rajkumar SV; Kyle RA; Hogan W; Kumar SK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2127-2132. PubMed ID: 29656139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
    Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
    J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of multiple myeloma.
    Minnie SA; Hill GR
    J Clin Invest; 2020 Apr; 130(4):1565-1575. PubMed ID: 32149732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.